S
SERB Pharmaceuticals
Acquirer counsel
Freshfields
Paul HumphreysOffice Managing Partner
Jeff JayPartner
Sebastian FainPartner
19 lawyers involved
Rainmaker
Loading page...
Freshfields advises SERB Pharmaceuticals on $412 million acquisition of Y-mAbs Therapeutics Inc
Deal Overview
- Value
- $412m
- Deal type
- M&A
- Structure
- Data in progress
- Status
- Data in progress
Advisors
ACQUIRER
Freshfields Overview
- SERB Pharmaceuticals is a portfolio company of Charterhouse Capital Partners, buying Y-mAbs Therapeutics, a Nasdaq-listed commercial-stage biopharmaceutical company focused on novel radioimmunotherapy and antibody-based therapeutic cancer products.
- The transaction is a take-private acquisition of Y-mAbs Therapeutics, Inc. by SERB Pharmaceuticals.
- The deal had been agreed by 2025-08-05, with SERB signing an agreement to acquire Y-mAbs in a control transaction.
Y
Y-mAbs Therapeutics, Inc.
Seller counsel
Seller counsel not yet recorded